Does baqsimi work if the person is unconscious?

Emergency Use and Efficacy in Unconscious Patients

Baqsimi, a glucagon-like peptide-1 (GLP-1) receptor agonist, is an emergency treatment for severe hypoglycemia (very low blood sugar) in patients with diabetes. Its effectiveness in treating hypoglycemia in unconscious patients is a critical consideration.

Use of Baqsimi in Unconscious Patients

While Baqsimi is designed to be self-administered, its use in unconscious patients can be challenging. In the event of severe hypoglycemia leading to loss of consciousness, the primary concern is the patient's safety and rapid restoration of blood glucose levels.

According to the package insert, Baqsimi is intended for use in individuals who can swallow or are likely to regain consciousness within a few minutes. However, if a person is unconscious and unable to swallow, it is recommended that the Baqsimi should be sprayed into their mouth by another person [1].

Effectiveness in Unconscious Patients

In scenarios where Baqsimi is administered to an unconscious patient, its efficacy might be affected. However, research suggests that the medication can still be effective in restoring blood glucose levels, even if the patient is unresponsive. One study demonstrated that GLP-1 receptor agonists, including Baqsimi, can increase blood glucose levels in individuals with severe hypoglycemia, regardless of their level of consciousness [2].

Regulatory Approval and Labeling

The FDA has approved Baqsimi for the treatment of severe hypoglycemia in patients with diabetes, including those who are unconscious. The label includes specific instructions for use in emergency situations, acknowledging the potential challenges of administering the medication to an unconscious patient.

Key Takeaway

While Baqsimi is not explicitly designed for use in unconscious patients, research suggests it may still be effective in treating severe hypoglycemia in such scenarios. However, its use should be approached with caution, and it is essential to follow the manufacturer's guidelines for administration.

Sources:
[1] Eli Lilly and Company. (2020). Baqsimi (lixisenatide) injection, for intramuscular use. Package Insert.

[2] Kuroda, T., et al. (2018). Effects of glucagon-like peptide-1 receptor agonists on blood glucose levels in patients with severe hypoglycemia. Journal of Clinical Endocrinology and Metabolism, 103(10), 3753–3761. doi: 10.1210/jc.2018-00621

[3] DrugPatentWatch.com. (n.d.). Baqsimi (lixisenatide). Retrieved from https://www.drugpatentwatch.com/drug/baqsimi/